What happened: A trial involving puberty blockers has been paused after the medicines regulator recommended raising the minimum participant age to 14. The decision follows concerns about the suitability of younger children in the study.
Why it matters:
- The pause affects children and families involved in the trial and those considering treatment options.
- It highlights ongoing scrutiny of medical treatments for young people undergoing puberty.
MNN Take: Regulators are reviewing age criteria to ensure safety and appropriateness in medical trials involving puberty blockers, reflecting careful oversight in sensitive treatments.
Sources: BBC Health (Lifestyle)